| Title: |
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+lymphoid malignancies |
| Authors: |
Frigault, Matthew J., Graham, Charlotte E., Berger, Trisha R., Ritchey, Julie, Horick, Nora K., El-Jawahri, Areej, Scarfò, Irene, Schmidts, Andrea, Haradhvala, Nicholas J., Wehrli, Marc, Lee, Won-Ho, Parker, Aiyana L., Wiggin, Hadley R., Bouffard, Amanda, Dey, Aonkon, Leick, Mark B., Katsis, Katelin, Elder, Eva L., Dolaher, Maria A., Cook, Daniella T., Chekmasova, Alena A., Huang, Lu, Nikiforow, Sarah, Daley, Heather, Ritz, Jerome, Armant, Myriam, Preffer, Fred, DiPersio, John F., Nardi, Valentina, Chen, Yi-Bin, Gallagher, Kathleen M. E., Maus, Marcela V. |
| Source: |
Blood; September 2024, Vol. 144 Issue: 11 p1153-1167, 15p |
| Abstract: |
•CAR-37 T cells expanded to >98% of T cells and led to complete responses but caused severe cytopenia associated with high levels of IL-18.•Depleting CAR-37 T cells using cetuximab to target the safety switch was unsuccessful in the setting of neutropenia. |
| Database: |
Supplemental Index |
